科学研究

  • 学术报告:表面纳米结构与生...
    2020-10-13
  • 学术报告:原子尺度上分子间...
    2020-08-28
  • 学术报告:代谢组学在人群研...
    2020-08-25

会员登录

用户名:
密码:

2021年度论文动态

ADAR1 Stimulation by IFN-a Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response

Tao Li 1, Xiaoshuang Yang 1, Wei Li 2, Jiaru Song 1, Zhuo Li 3, Xilin Zhu 1, Xiaopan Wu 4, Ying Liu 5

 

Mol Ther. 2020 Dec 3;S1525-0016(20)30657-2. doi: 10.1016/j.ymthe.2020.11.031.

PMID: 33279720

 

Abstract

The partial response of chronic hepatitis B virus (CHB) patients to interferon-α (IFN-α) therapy remains elusive, which requires a better understanding of the involved molecular mechanism. In our study, bioinformatics analysis was applied to relate IFN-α regulated candidate genes and RNA editing sites by RNA sequencing. Mitochondrial antiviral signaling protein (MAVS) antiviral effect was confirmed in HepG2.2.15 cells and in two mouse models. The associations between polymorphisms in MAVS gene and response to IFN-α therapy were confirmed in CHB patients. We found that IFN-α downregulates MAVS via RNA editing that was mediated by adenosine deaminase acting on RNA (ADAR1). ADAR1 inhibited MAVS expression via a human antigen R (HuR)-mediated post-transcriptional regulation. MAVS exerted an antiviral activity and reduced the level of hepatitis B virus (HBV) markers in vitro and in vivo. IFN-α antiviral effects were significantly enhanced by MAVS co-transfection. Hepatitis B core protein (HBc) interacted with SP1 to inhibit the promoter activity of MAVS that regulates its expression. CHB patients with a rs3746662A allele had higher MAVS expression and thus were more responsive to IFN-α treatment. In this work, we demonstrated that the decrease of MAVS expression is mediated by the IFN-α-ADAR1 axis. This study also highlighted the potential for the clinical application of MAVS in combination with IFN-α for the treatment of HBV infection.